1. Home
  2. FGI vs TPST Comparison

FGI vs TPST Comparison

Compare FGI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FGI

FGI Industries Ltd.

N/A

Current Price

$7.78

Market Cap

14.5M

Sector

Industrials

ML Signal

N/A

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

N/A

Current Price

$0.51

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FGI
TPST
Founded
1987
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.5M
13.7M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
FGI
TPST
Price
$7.78
$0.51
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $10.00
N/A
AVG Volume (30 Days)
8.6K
★ 237.3K
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.17
N/A
Revenue
N/A
★ $295,000.00
Revenue This Year
$3.45
N/A
Revenue Next Year
$5.39
N/A
P/E Ratio
$49.53
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.14
$0.50
52 Week High
$19.93
$10.45

Technical Indicators

Market Signals
Indicator
FGI
TPST
Relative Strength Index (RSI) 52.81 28.68
Support Level $6.64 N/A
Resistance Level $8.23 $1.24
Average True Range (ATR) 0.59 0.05
MACD 0.07 -0.00
Stochastic Oscillator 54.48 1.83

Price Performance

Historical Comparison
FGI
TPST

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, it generates the majority of its revenue from the United States, followed by Canada and Europe.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: